Drug intelligence / Profile preview

FT-019

Development stage: Preclinical
Lead developer: Frontera Therapeutics
Modality: Gene Therapies

Overview

**FT-019** is an investigational **rAAV gene therapy** program from **Fronterra** for an undisclosed **degenerative ophthalmic disorder**. Based on Fronterra's pipeline, the program remains **preclinical**, and neither the specific molecular target nor the transgene payload has been publicly disclosed. As an rAAV-based ocular gene therapy, FT-019 is intended to deliver a therapeutic genetic payload to eye tissues to modify disease biology in a degenerative retinal or related ophthalmic setting, but its precise mechanism, administration route, and manufacturing details have not been stated publicly.

Beyond the preview

Go deeper on FT-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT-019.

Explore the full profile